Q&A

Psychiatric Times is pleased to present a brand-new section on media and psychiatry, and section editor, Mena Mirhom, MD, FAPA.

Stephen Mateka, DO, Psychiatric Times' new Child & Adolescent Psychiatry Section Editor, shares thoughts and insights.

Learn more about how cognitive behavior therapy can be used as a healing tool in marginalized communities.

With art we build what poverty destroys.

A therapist asks a question that makes me glimpse the eternal.

The PDUFA date for KarXT for schizophrenia is September 26, 2024. Here’s what one expert thinks of this potential treatment.

Tomorrow, August 31, is Overdose Awareness Day. What can you be doing to help prevent overdose deaths?

Art informs life and life informs art.

Art imitates life imitates art.

How are eating disorders different in LGBTQ+ patients compared with cisgender heterosexual patients? How can you best help manage eating disorders in this patient population?

Psychiatric Times asked H. Steven Moffic, MD, to share his thoughts on humanitarianism and psychiatry.

What does being a humanitarian mean to H. Steven Moffic, MD, winner of the 22024 Abraham L. Halpern Humanitarian Award?

Transgender individuals are 4 times as likely as their cisgender peers to have a mental illness. Check out these culturally competent care strategies and tips to provide the best possible care.

Andrew Krystal, MD, and Wayne Drevets, MD, share their thoughts on the recent seltorexant data presented at the 2024 ASCP Annual Meeting.

What questions did a Milwaukee community of older adults have for a psychiatrist?

The FDA Meeting of the Psychopharmacologic Drugs Advisory Committee evaluating the New Drug Application for MDMA is happening now. How do clinicians feel about this potential treatment for PTSD?

Rakesh Jain, MD, shares more about the recent approval of Austedo XR for the treatment of tardive dyskinesia and Huntington disease chorea control.

A lead educator and clinical consultant in the Lykos Therapeutics MDMA Therapist Education Program discusses MDMA-assisted therapy’s potential.

Some clinicians are skeptical about the potential of MDMA-assisted therapy...

If approved, how will MDMA-assisted therapy impact clinical psychiatry? The CEO of Lykos Therapeutics shares her thoughts.

In advance of the June 4 FDA Advisory Committee Meeting on MDMA-assisted therapy, we sat down with Alejandra Alva, MD, to get his first impressions.

Sam Clark, MD, PhD, the founder and CEO of Terran Biosciences shared all you need to know about the development of their schizophrenia treatment, TerXT.

In honor of Asian American/Pacific Islander Heritage Month, we had a discussion on how best to support AAPI youth and their families.

Petros Levounis, MD, MA, talks addiction, buprenorphine, his year as president of the APA, and more at the 2024 Annual Meeting.

What does the recent FDA clearance of this treatment for adolescents mean for the future of MDD treatment?

What are the most effective approaches to SUD treatment in this unique patient population?

Rosine Perelberg, PhD, discusses psychoanalytic thought, social anthropology, and the future of psychoanalysis.

Rejoyn was recently cleared by the FDA, making it the first prescription digital therapeutic for major depressive disorder.

Join us in congratulating Dr Tampi on his recent win of the American Association for Geriatric Psychiatry’s Diversity Award!

Elena Koundourakis, the head of the Orexin Franchise Development and Portfolio Strategy at Takeda, shares her thoughts on the recent positive topline results from a phase 2 trial evaluating TAK-861, an oral orexin receptor 2 agonist, in patients with narcolepsy type 1.